Search Filters. Trial Filters. A listing of Pathumthani, Thailand clinical trials actively recruiting patients volunteers. The study consists of the following periods: screening; treatment; post-treatment follow up, safety follow up, long term and survival follow-up. The purpose of this study is to compare blood loss between using low dose mg and high dose 3 g topical intra-articular tranexamic acid after total knee arthroplasty in double-blind RCT. The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease.
The participant will either get semaglutide active medicine or placebo "dummy" medicine. Which treatment the participants get is decided by chance. This implementation study aims to evaluate the efficacy, acceptability, and safety of first-trimester screening and prevention for preterm-preeclampsia. The study involves a period where no intervention will take place at all Polyclonal antibodies against IMU peptides bind three separate regions of the HER2 receptor and also to the dimerization loop of the HER2 receptor, preventing dimerization, which in turn inhibits intracellular signaling.
To compare the effect of each herb extracts in form of mouth wash to protect or delay the onset of the radiation-induced mucositis from the adverse effects of radiation therapy in patients with head and neck cancer. Background : Liver cancer is a serious disease with a high death rate. One of the treatment modalities for liver cancer is TACE. Patients always scare of the first TACE due to their lack of knowledge and inadequate comprehension of the procedure.
Hence, they crave to have a good quality This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma HCC who are at high risk for disease recurrence.
This study will evaluate the efficacy, safety, and pharmacokinetics of GDC in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor HR -positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant Powered by.
